SCARB1 G2S - GET-Evidence

Note: This variant has not been sufficiently evaluated by a GET-Evidence editor.

To be considered sufficiently evaluated a variant must have both "variant evidence" and "clinical importance" scores filled in.

Please help improve GET-Evidence by evaluating evidence for this variant!

Curation:
Currentness:

(See the latest version)

SCARB1 G2S

(SCARB1 Gly2Ser)


You are viewing an old version of this page that was saved on February 12, 2010 at 9:00am by Abraham Rosenbaum.

Edited in this revision:

Short summary

Higher responsiveness to fenofibrate.

Variant evidence
Computational -
Functional -
Case/Control -
Familial -
 
Clinical importance
Severity -
Treatability -
Penetrance -
 

Impact

Insufficiently evaluated pharmacogenetic

(The "insufficiently evaluated" qualifier is assigned automatically based on the above evidence and importance scores.)

Inheritance pattern

unknown

Summary of published research, and additional commentary

 

Allele frequency

  • T @ chr12:125348263: 8.1% (816/10032) in EVS
  • Frequency shown in summary reports: 8.1% (816/10032)

Publications
 

Genomes
 

NA12878

 

Other external references
 

    PharmGKB
  • [fenofibrate]
    This variant was significantly associated with postfenofibrate change for triglycerides. Subjects bearing minor allele A tend to have higher responsiveness to fenofibrate in lowering TG. A total of 1,327 subjects (639 men and 688 women) from 148 families were genotyped. Of these 1,327 subjects, 861 subjects (427 men and 434 women) went through the fenofibrate trial and had complete lipid phenotype and genotype data.
    www.ncbi.nlm.nih.gov/pubmed/18542840
    PolyPhen-2
  • Score: 0.937 (probably damaging)

Other in silico analyses
 

  • NBLOSUM100 score = 2
  • GET-Evidence autoscore = 2

Edit history
 

Gene search

"GENE" or "GENE A123C":

Log in